159 related articles for article (PubMed ID: 1367966)
1. Antisense oligonucleotides for therapeutic intervention.
Eck SL; Nabel GJ
Curr Opin Biotechnol; 1991 Dec; 2(6):897-904. PubMed ID: 1367966
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
4. Patent review: therapeutic applications for antisense oligonucleotides 1999-2000.
Orr RM; O'Neill CF
Curr Opin Mol Ther; 2000 Jun; 2(3):325-31. PubMed ID: 11249627
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides: a new therapeutic approach.
Temsamani J; Guinot P
Biotechnol Appl Biochem; 1997 Oct; 26(2):65-71. PubMed ID: 9357101
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapy in oncology: new hope for an old idea?
Tamm I; Dörken B; Hartmann G
Lancet; 2001 Aug; 358(9280):489-97. PubMed ID: 11513935
[TBL] [Abstract][Full Text] [Related]
7. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
8. Antisense oligonucleotides: the state of the art.
Aboul-Fadl T
Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic oligonucleotides: the road not taken.
Stein CA; Goel S
Clin Cancer Res; 2011 Oct; 17(20):6369-72. PubMed ID: 21862637
[TBL] [Abstract][Full Text] [Related]
10. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
12. Application of modified antisense oligonucleotides and siRNAs as antiviral drugs.
Wagner A; Bock CT; Fechner H; Kurreck J
Future Med Chem; 2015; 7(13):1637-42. PubMed ID: 26381598
[No Abstract] [Full Text] [Related]
13. In vivo electroporetic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats.
Baba M; Iishi H; Tatsuta M
Int J Cancer; 2000 Jan; 85(2):260-6. PubMed ID: 10629087
[TBL] [Abstract][Full Text] [Related]
14. Current status of delivery systems to improve target efficacy of oligonucleotides.
Shoji Y; Nakashima H
Curr Pharm Des; 2004; 10(7):785-96. PubMed ID: 15032703
[TBL] [Abstract][Full Text] [Related]
15. A status update of modified oligonucleotides for chemotherapeutics applications.
Sanghvi YS
Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
[TBL] [Abstract][Full Text] [Related]
16. Antisense inhibition of virus infections.
Kilkuskie RE; Field AK
Adv Pharmacol; 1997; 40():437-83. PubMed ID: 9217933
[TBL] [Abstract][Full Text] [Related]
17. Oligonucleotide-based therapeutic options against hepatitis C virus infection.
Trepanier JB; Tanner JE; Alfieri C
Antivir Ther; 2006; 11(3):273-87. PubMed ID: 16759043
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of Antisense Drugs.
Bennett CF; Baker BF; Pham N; Swayze E; Geary RS
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():81-105. PubMed ID: 27732800
[TBL] [Abstract][Full Text] [Related]
19. Antisense and antiviral therapy.
Sherman MI
Ann N Y Acad Sci; 1990; 616():201-4. PubMed ID: 2127663
[No Abstract] [Full Text] [Related]
20. DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes.
Fokina AA; Stetsenko DA; François JC
Expert Opin Biol Ther; 2015 May; 15(5):689-711. PubMed ID: 25772532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
